Author:
Pothier Kristell, ,Saint-Aubert Laure,Hooper Claudie,Delrieu Julien,Payoux Pierre,de Souto Barreto Philipe,Vellas Bruno
Funder
French Ministry of Health
Institut de Recherche Pierre Fabre
Avid radiopharmaceuticals Eli Lilly and Company
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference25 articles.
1. Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol 10(7):667–670
2. Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, Ren WD (2014) Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine 93:27
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, … Park DC (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. J Alzheimer’s Assoc 7(3):280–292
4. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603–1606.
https://doi.org/10.1212/01.wnl.0000260969.94695.56
5. Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s Dement 6:108–121
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献